LENZ Therapeutics, Inc. (LENZ) EPS (Weighted Average and Diluted) (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with -$12.05 as the latest value for Q4 2023.
- On a quarterly basis, EPS (Weighted Average and Diluted) fell 2638.64% to -$12.05 in Q4 2023 year-over-year; TTM through Dec 2023 was -$19.91, a 976.22% decrease, with the full-year FY2024 number at -$2.34, up 93.45% from a year prior.
- EPS (Weighted Average and Diluted) was -$12.05 for Q4 2023 at LENZ Therapeutics, down from -$0.39 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.39 in Q3 2023 to a low of -$12.05 in Q4 2023.